Haemonetics (NYSE:HAE) had its target price boosted by analysts at Jefferies Group from $18.00 to $75.00 in a note issued to investors on Monday, The Fly reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Jefferies Group’s target price suggests a potential upside of 19.62% from the company’s current price.
HAE has been the topic of several other research reports. Morgan Stanley restated an “equal weight” rating and set a $43.00 price objective (up previously from $38.00) on shares of Haemonetics in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a report on Wednesday, October 25th. Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a report on Tuesday, January 2nd. Barrington Research boosted their price objective on shares of Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Finally, Craig Hallum reissued a “hold” rating and issued a $50.00 target price (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $57.83.
Haemonetics (HAE) opened at $62.70 on Monday. Haemonetics has a 52 week low of $36.44 and a 52 week high of $63.90. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. The company has a market cap of $3,311.70, a P/E ratio of 783.85, a P/E/G ratio of 4.71 and a beta of 0.99.
In related news, CFO Willaim P. Burke sold 13,193 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the completion of the sale, the chief financial officer now directly owns 27,227 shares of the company’s stock, valued at $1,471,347.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Susan Bartlett Foote sold 16,926 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $54.19, for a total transaction of $917,219.94. Following the sale, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The disclosure for this sale can be found here. Insiders have sold 54,486 shares of company stock worth $3,050,827 over the last quarter. 1.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of HAE. Riverhead Capital Management LLC increased its stake in Haemonetics by 79.3% in the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares in the last quarter. Pacad Investment Ltd. bought a new stake in Haemonetics in the second quarter valued at approximately $174,000. Shelton Capital Management bought a new stake in Haemonetics in the second quarter valued at approximately $204,000. Cubist Systematic Strategies LLC bought a new stake in Haemonetics in the second quarter valued at approximately $260,000. Finally, SG Americas Securities LLC bought a new stake in Haemonetics in the third quarter valued at approximately $316,000.
About Haemonetics
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
